Insulet Shows Improved Relative Price Performance; Still Shy Of Benchmark

The Relative Strength (RS) Rating for Insulet (PODD) entered a higher percentile Wednesday, as it got a lift from 68 to 71.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price behavior over the last 52 weeks stacks up against all the other stocks in our database.

Decades of market research reveals that the best stocks often have an RS Rating of above 80 in the early stages of their moves. See if Insulet can continue to show renewed price strength and clear that threshold.

See How IBD Helps You Make More Money In Stocks

Insulet is within a buy zone after climbing above a 290.10 entry in a flat base. Once a stock moves 5% or higher beyond the initial entry, it’s considered out of buy range.

The company reported -268% EPS growth in the latest quarterly report, while sales growth came in at 16%.

The company holds the No. 48 rank among its peers in the Medical-Products industry group. Bio Rad Labs (BIOB) and Staar Surgical (STAA) are also among the group’s highest-rated stocks.


Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Evaluate Any Stock With Stock Ratings, IBD Charts And Stock Checkup

Most Related Links :
honestcolumnist Governmental News Finance News

Source link

Back to top button